Literature DB >> 28545337

Evaluation of different recall periods for the US National Cancer Institute's PRO-CTCAE.

Tito R Mendoza1, Amylou C Dueck2, Antonia V Bennett3, Sandra A Mitchell4, Bryce B Reeve3, Thomas M Atkinson5, Yuelin Li5, Kathleen M Castro4, Andrea Denicoff4, Lauren J Rogak5, Richard L Piekarz4, Charles S Cleeland1, Jeff A Sloan6, Deborah Schrag7, Ethan Basch3,5.   

Abstract

AIMS: The US National Cancer Institute recently developed the PRO-CTCAE (Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events). PRO-CTCAE is a library of questions for clinical trial participants to self-report symptomatic adverse events (e.g. nausea). The objective of this study is to inform evidence-based selection of a recall period when PRO-CTCAE is included in a trial. We evaluated differences between 1-, 2-, 3-, and 4-week recall periods, using daily reporting as the reference.
METHODS: English-speaking patients with cancer receiving chemotherapy and/or radiotherapy were enrolled at four US cancer centers and affiliated community clinics. Participants completed 27 PRO-CTCAE items electronically daily for 28 days, and then weekly over 4 weeks, using 1-, 2-, 3-, and 4-week recall periods. For each recall period, mean differences, effect sizes, and intraclass correlation coefficients were calculated to evaluate agreement between the maximum of daily ratings and the corresponding ratings obtained using longer recall periods (e.g. maximum of daily scores over 7 days vs 1-week recall). Analyses were repeated using the average of daily scores within each recall period rather than the maximum of daily scores.
RESULTS: A total of 127 subjects completed questionnaires (57% male; median age: 57). The median of the 27 mean differences in scores on the PRO-CTCAE 5-point response scale comparing the maximum daily versus the longer recall period (and corresponding effect size) was -0.20 (-0.20) for 1-week recall, -0.36 (-0.31) for 2-week recall, -0.45 (-0.39) for 3-week recall, and -0.47 (-0.40) for 4-week recall. The median intraclass correlation across 27 items between the maximum of daily ratings and the corresponding longer recall ratings for 1-week recall was 0.70 (range: 0.54-0.82), for 2-week recall was 0.74 (range: 0.58-0.83), for 3-week recall was 0.72 (range: 0.61-0.84), and for 4-week recall was 0.72 (range: 0.64-0.86). Similar results were observed for all analyses using the average of daily scores rather than the maximum of daily scores.
CONCLUSION: A 1-week recall corresponds best to daily reporting. Although intraclass correlations remain stable over time, there are small but progressively larger differences between daily and longer recall periods at 2, 3, and 4 weeks, respectively. The preferred recall period for the PRO-CTCAE is the past 7 days, although investigators may opt for recall periods of 2, 3, or 4 weeks with an understanding that there may be some information loss.

Entities:  

Keywords:  PRO-CTCAE; Recall period; measurement properties; patient-reported outcomes; symptomatic adverse events; validation

Mesh:

Substances:

Year:  2017        PMID: 28545337      PMCID: PMC5448293          DOI: 10.1177/1740774517698645

Source DB:  PubMed          Journal:  Clin Trials        ISSN: 1740-7745            Impact factor:   2.486


  14 in total

1.  Interference with activities due to pain and fatigue: accuracy of ratings across different reporting periods.

Authors:  Joan E Broderick; Stefan Schneider; Joseph E Schwartz; Arthur A Stone
Journal:  Qual Life Res       Date:  2010-06-11       Impact factor: 4.147

2.  Optimal recall periods for patient-reported outcomes: challenges and potential solutions.

Authors:  Donald E Stull; Nancy Kline Leidy; Bhash Parasuraman; Olivier Chassany
Journal:  Curr Med Res Opin       Date:  2009-04       Impact factor: 2.580

3.  Comparison of seven-day and repeated 24-hour recall of symptoms in the first 100 days after hematopoietic cell transplantation.

Authors:  William A Wood; Allison M Deal; Antonia V Bennett; Sandra A Mitchell; Amy P Abernethy; Ethan Basch; Charlotte Bailey; Bryce B Reeve
Journal:  J Pain Symptom Manage       Date:  2014-08-13       Impact factor: 3.612

4.  Comparison of 7-day and repeated 24-hour recall of symptoms of cystic fibrosis.

Authors:  Antonia V Bennett; Donald L Patrick; James F Lymp; Todd C Edwards; Christopher H Goss
Journal:  J Cyst Fibros       Date:  2010-12       Impact factor: 5.482

5.  Choice of recall period for patient-reported outcome (PRO) measures: criteria for consideration.

Authors:  Josephine M Norquist; Cynthia Girman; Sheri Fehnel; Carla DeMuro-Mercon; Nancy Santanello
Journal:  Qual Life Res       Date:  2011-09-10       Impact factor: 4.147

6.  The accuracy of pain and fatigue items across different reporting periods.

Authors:  Joan E Broderick; Joseph E Schwartz; Gregory Vikingstad; Michelle Pribbernow; Steven Grossman; Arthur A Stone
Journal:  Pain       Date:  2008-05-01       Impact factor: 6.961

7.  Cognitive interviewing of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Authors:  Jennifer L Hay; Thomas M Atkinson; Bryce B Reeve; Sandra A Mitchell; Tito R Mendoza; Gordon Willis; Lori M Minasian; Steven B Clauser; Andrea Denicoff; Ann O'Mara; Alice Chen; Antonia V Bennett; Diane B Paul; Joshua Gagne; Lauren Rogak; Laura Sit; Vish Viswanath; Deborah Schrag; Ethan Basch
Journal:  Qual Life Res       Date:  2013-07-20       Impact factor: 4.147

Review 8.  Recommended patient-reported core set of symptoms to measure in adult cancer treatment trials.

Authors:  Bryce B Reeve; Sandra A Mitchell; Amylou C Dueck; Ethan Basch; David Cella; Carolyn Miller Reilly; Lori M Minasian; Andrea M Denicoff; Ann M O'Mara; Michael J Fisch; Cynthia Chauhan; Neil K Aaronson; Corneel Coens; Deborah Watkins Bruner
Journal:  J Natl Cancer Inst       Date:  2014-07-08       Impact factor: 13.506

9.  Comparison of 7-day recall and daily diary reports of COPD symptoms and impacts.

Authors:  Antonia V Bennett; Dagmar Amtmann; Paula Diehr; Donald L Patrick
Journal:  Value Health       Date:  2012-02-09       Impact factor: 5.725

10.  Mode equivalence and acceptability of tablet computer-, interactive voice response system-, and paper-based administration of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Authors:  Antonia V Bennett; Amylou C Dueck; Sandra A Mitchell; Tito R Mendoza; Bryce B Reeve; Thomas M Atkinson; Kathleen M Castro; Andrea Denicoff; Lauren J Rogak; Jay K Harness; James D Bearden; Donna Bryant; Robert D Siegel; Deborah Schrag; Ethan Basch
Journal:  Health Qual Life Outcomes       Date:  2016-02-19       Impact factor: 3.186

View more
  23 in total

1.  Chemotherapy-induced nausea and vomiting (CINV) in patients with advanced lung cancer during the first-line treatment: assessment by physicians, nurses, and patients from an Italian multicenter survey.

Authors:  S Carnio; D Galetta; V Scotti; D L Cortinovis; A Antonuzzo; S Pisconti; A Rossi; O Martelli; F L Cecere; A Lunghi; A Del Conte; E S Montagna; J Topulli; D Pelizzoni; S G Rapetti; M Gianetta; M V Pacchiana; V Pegoraro; N Cataldo; E Bria; S Novello
Journal:  Support Care Cancer       Date:  2017-12-21       Impact factor: 3.603

2.  Multidimensional Pain Assessment Tools for Ambulatory and Inpatient Nursing Practice.

Authors:  Clara Scher; Emily Petti; Lauren Meador; Janet H Van Cleave; Eva Liang; M Carrington Reid
Journal:  Pain Manag Nurs       Date:  2020-05-21       Impact factor: 1.929

3.  Patient-Reported Toxicities During Chemotherapy Regimens in Current Clinical Practice for Early Breast Cancer.

Authors:  Kirsten A Nyrop; Allison M Deal; Shlomit S Shachar; Ethan Basch; Bryce B Reeve; Seul Ki Choi; Jordan T Lee; William A Wood; Carey K Anders; Lisa A Carey; Elizabeth C Dees; Trevor A Jolly; Katherine E Reeder-Hayes; Gretchen G Kimmick; Meghan S Karuturi; Raquel E Reinbolt; JoEllen C Speca; Hyman B Muss
Journal:  Oncologist       Date:  2018-12-14

Review 4.  Pharmacological Treatments Available for Immune-Checkpoint-Inhibitor-Induced Colitis.

Authors:  Sae Ohwada; Keisuke Ishigami; Noriyuki Akutsu; Hiroshi Nakase
Journal:  Biomedicines       Date:  2022-06-06

5.  Clinical Utility and User Perceptions of a Digital System for Electronic Patient-Reported Symptom Monitoring During Routine Cancer Care: Findings From the PRO-TECT Trial.

Authors:  Ethan Basch; Angela M Stover; Deborah Schrag; Arlene Chung; Jennifer Jansen; Sydney Henson; Philip Carr; Brenda Ginos; Allison Deal; Patricia A Spears; Mattias Jonsson; Antonia V Bennett; Gita Mody; Gita Thanarajasingam; Lauren J Rogak; Bryce B Reeve; Claire Snyder; Lisa A Kottschade; Marjory Charlot; Anna Weiss; Deborah Bruner; Amylou C Dueck
Journal:  JCO Clin Cancer Inform       Date:  2020-10

6.  The development, usability, and reliability of the Electronic Patient Visit Assessment (ePVA) for head and neck cancer.

Authors:  Janet H Van Cleave; Mei R Fu; Antonia V Bennett; Mark S Persky; Zujun Li; Adam Jacobson; Kenneth S Hu; Allison Most; Catherine Concert; Maria Kamberi; Jacqueline Mojica; Amanda Peyser; Ann Riccobene; Anh Tran; Michael J Persky; Justin Savitski; Eva Liang; Brian L Egleston
Journal:  Mhealth       Date:  2019-07-29

7.  Comparison of weekly and daily recall of pain as an endpoint in a randomized phase 3 trial of cabozantinib for metastatic castration-resistant prostate cancer.

Authors:  Elisabeth M Schaffer; Ethan M Basch; Gisela M Schwab; Antonia V Bennett
Journal:  Clin Trials       Date:  2021-04-22       Impact factor: 2.486

8.  One-Year Quality of Life Post-Pneumonia Diagnosis in Japanese Adults.

Authors:  Henry A Glick; Taiga Miyazaki; Katsuji Hirano; Elisa Gonzalez; Luis Jodar; Bradford D Gessner; Raul E Isturiz; Adriano Arguedas; Shigeru Kohno; Jose A Suaya
Journal:  Clin Infect Dis       Date:  2021-07-15       Impact factor: 9.079

9.  Japanese translation and linguistic validation of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Authors:  Tempei Miyaji; Yukiko Iioka; Yujiro Kuroda; Daigo Yamamoto; Satoru Iwase; Yasushi Goto; Masahiro Tsuboi; Hiroki Odagiri; Yu Tsubota; Takashi Kawaguchi; Naoko Sakata; Ethan Basch; Takuhiro Yamaguchi
Journal:  J Patient Rep Outcomes       Date:  2017-12-05

Review 10.  Gastrointestinal toxicity of immune checkpoint inhibitors: from mechanisms to management.

Authors:  Mark A Samaan; Polychronis Pavlidis; Sophie Papa; Nick Powell; Peter M Irving
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2018-03-07       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.